

10 April 2019

N4 Pharma Plc
("N4 Pharma" or the "Company")

Director/PDMR shareholding

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments, announces that Nigel Theobald, Chief Executive Officer of the Company, has purchased 67,343 ordinary shares in the Company ("Ordinary Shares") at a price of 4.44 pence per Ordinary Share. In addition, Anne-Marie Lawrence, wife of Nigel Theobald and a person closely associated with him, has today purchased 67,343 Ordinary Shares at a price of 4.44 pence per Ordinary Share.

As a result of these purchases, Nigel Theobald's interest in the Company is now 16,981,319 Ordinary Shares, which represents approximately 16.74 per cent. of Company's issued share capital.

Enquiries:

N4 Pharma Plc

Nigel Theobald, CEO

Via Alma PR

Allenby Capital Limited

James Reeve/Asha Chotai

Tel: +44(0)203 328 5656

Scott PR

Georgia Smith

Tel: +44(0)1477 539 539

About N4 Pharma plc

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for vaccines and cancer treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the

required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:

1	Details of the person discharging managerial responsibilities / person closely associated			
a)	Name	Nigel Theobald		
2	Reason for the notification			
a)	Position/status	Chief Executive Officer		
b)	Initial notification /Amendment	Initial notification		
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor			
a)	Name	N4 Pharma PLC		
b)	LEI	213800I841D2RKMFK955		
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted			
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 0.4p GB00BYW8QM32		
b)	Nature of the transaction	Purchase of ordinary shares in the Company		
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		4.44p	67,343	
d)	Aggregated	Aggregated volume: 67,343		

	information - Aggregated volume - Price	Weighted average price: 4.44 pence per share
e)	Date of the transaction	10 April 2019
f)	Place of the transaction	London Stock Exchange, XLON

1	Details of the person discharging managerial responsibilities / person closely associated			
a)	Name	Anne-Marie Lawrence		
2	Reason for the notification			
a)	Position/status	Wife and PCA of Chief Executive Officer		
b)	Initial notification /Amendment	Initial notification		
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor			
a)	Name	N4 Pharma PLC		
b)	LEI	213800I841D2RKMFK955		
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted			
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 0.4p GB00BYW8QM32		
b)	Nature of the transaction	Purchase of ordinary shares in the Company		
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		4.44	67,343	

d)	Aggregated information - Aggregated volume - Price	Aggregated volume: 67,343 Weighted average price: 4.44 pence per share
e)	Date of the transaction	10 April 2019
f)	Place of the transaction	London Stock Exchange, XLON

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHEAELEFSENEFF